Piper sarmentosum Roxb. produces antidepressant-like effects in rodents, associated with activation of the CREB-BDNF-ERK signalling pathway and reversal of HPA axis hyperactivity. by Li, Q et al.
Piper sarmentosum Roxb. produces antidepressant-like effects in rodents, associated 
with activation of the CREB-BDNF-ERK signalling pathway and reversal of HPA 
axis hyperactivity 
 
Qing Lia,b,1, Fa-Lin Qub,1, Yue Gaoa, Yi-Ping Jianga, Khalid Rahmanc, Kuo-Hsiung 
Leed, Ting Hana,d*, Lu-Ping Qina,* 
aDepartment of Pharmacognosy, School of Pharmacy, Second Military Medical University, 325 
Guohe Road, Shanghai 200433, PR China 
bThe 102nd Hospital of PLA, 55 Heping North Road, Changzhou 213003, PR China 
cFaculty of Science, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores 
University, Byrom Street, Liverpool, L3 3AF, UK 
dNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of 
North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599-7568, United States. 
1These authors contributed equally to this research. 
 
Corresponding author： 
Prof. Dr. Ting Han,  
Tel: +86 21 81871306; Fax: +86 21 81871306; E-Mail: than927@163.com 
Prof. Dr. Lu-ping Qin,  






Ethnopharmacological relevance: There are many plants of genus Piper which have been 
reported to induce antidepressant-like effects, Piper sarmentosum (PS) is one of them. PS is a 
Chinese herbal medicine and a traditional edible vegetable. 
Materials and Methods: In the present study, the antidepressant-like effects of PS extracts 
and the ethyl acetate fraction of PS extracts (PSY) were assessed using the open field test (OFT), 
forced swimming test (FST), and tail suspension test (TST) in mice. Furthermore, we applied a 4 
consecutive weeks of chronic unpredictable mild stress (CUMS) as a model of depression in rats, 
followed by a sucrose preference test. Then we examined the possible mechanisms of this action. 
The activity of the hypothalamic–pituitary–adrenal (HPA) axis was evaluated by detecting the 
serum corticosterone (CORT) concentrations, and the protein expression levels of brain-derived 
neurotrophic factor (BDNF), the phosphorylated form CREB and ERK1/2 were detected by 
qRT-PCR or Western blot.  
Results: The results showed that PS extracts (100, 200 mg/kg) and PSY (12.5, 25, 50 mg/kg) 
treatment produced antidepressant-like effects in mice similar to fluoxetine (20 mg/kg), indicated 
by the reduced immobility time in the FST and TST, while both had no influence on the locomotor 
activity in the OFT. PSY treatment significantly increased sucrose preference and reduced serum 
CORT levels in CUMS rats. Moreover, PSY up-regulated BDNF protein levels, and increased 
CREB and ERK phosphorylation levels in the hippocampus on CUMS rats.  
Conclusions: These findings suggest that the antidepressant-like effects of PS extracts and 
PSY are mediated, at least in part, by modulating HPA axis, BDNF, CREB and ERK 
phosphorylation and expression in the hippocampus. 
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1. Introduction 
Depression is a syndrome of abnormal mood and a widespread mental disorder with a 
lifetime prevalence of 16.2% (Kessler et al., 2003). Despite decades of clinical experience, the 
definite mechanism underlying depression development is still poorly understood. Nowadays, the 
current antidepressants used clinically are chemical synthetic compounds with significant side 
effects and have low rates of remission and response (Sarko, 2000). Thus, better antidepressants 
with higher efficacy and safety are urgently needed. At present, numerous herbal medicines with 
antidepressant effects have become the focus of attention for the treatment of depression because 
the natural plant extracts have higher safety, such as Hypericum perforatum L. (HP, also called St 
John’s Wort), which is a worldwide well-known herbal antidepressant (Sarris et al., 2011), and the 
randomized clinical studies have shown that HP extracts are significantly superior to placebo 
(Lecrubier et al., 2002) and have similarly effects as standard antidepressants (Szegedi et al., 2005) 
in the treatment of depression.. Several human clinical trials have also provided preliminary 
positive evidence of antidepressant effects of some herbs, such as Echiumamoenum, Crocus 
sativus, Rhodiolarosea and Piper methysticum (Sarris et al., 2011).Therefore, herbal medicines 
have become a compelling part of pharmacotherapy in the treatment of depression (Thachil et al., 
2007). 
The genus Piper is an important member of the family–Piperaceae in medicine, consisting of 
about 2000 species and approximately 60 species are distributed in the tropical areas of China. 
However, several recent researches have indicated that some plants of genus Piper, for instance, 
Piper methysticum (Sarris et al., 2011) (commonly known as Kava–Kava), Piper laetispicum 
C.DC. (Xie et al., 2011) and Piper sarmentosum (PS) (Wu, 2002) have antidepressant effects. 
Kava-Kava used to be a popular antidepressant used all around the world, but is now banned 
because of hepatotoxicity (Teschke et al., 2009). PS, one of the genus Piper plants distributed in 
the India, Vietnam, Indonesia, Philippines, Malaysia and southern part of China, such as Yun nan, 
Guang xi, Fu jian, and Hai nan Province. It is reported that PS has biological activities, including: 
antioxidant (Ugusman et al., 2010), anti–tuberculosis (Hussain et al., 2008), anti–atherosclerosis 
(Amran et al., 2011), fracture healing (Estai et al., 2011), osteoporotic (Suhana Mohd Ramli et al., 
2013). In China, it has been used for treating toothache, beriberi, and abdominal distension by the 
local population (SATCM, 1999). PS also plays an important role in dealing with insomnia, 
anxiety and depression by indigene in the minority national areas of Yun nan, China (Huang et al., 
2005). The local people grind the steam and leaf of PS into a powder, then they soak the powder 
into Chinese liquor for a month. It is reported that indigene treat insomnia, anxiety and depression 
by drinking such liquor. Moreover, it is worth mentioning that, PS plays an important role as a 
traditional edible vegetable in the southern part of China (Zheng et al., 2013) suggesting low 
toxicity. 
Several researches have indicated a critical role of monoaminergic hypothesis in the response 
to depression and modulation of stress (Hou et al., 2006). However, clinical experience over the 
years indicates that not all patients respond to existing monoamine–based antidepressants 
(Cassano and Fava, 2004; Trivedi et al., 2006). This suggests that the reduction in monoamine 
levels might not be the only pathogenic mechanism of depression. So, in recent years, 
investigations have focused on non–monoamine–based antidepressants (Berton and Nestler, 2006). 
A leading hypothesis of depression which has received a lot of attention is that the hyperactivity of 
hypothalamic–pituitary–adrenal (HPA) axis plays an important role in response to stress (Hofman 
and Swaab, 2010). It is well known that the corticosterone (CORT) level in blood rise during 
persistently stressful situation or depression (Sapolsky, 2000). Besides the hypothesis of HPA, 
numbers of studies suggest that neurotrophic factors and adult neurogenesis also play an important 
role in mediating the responses to antidepressants (Krishnan and Nestler, 2008). The brain- 
derived neurotrophic factor (BDNF) has been demonstrated to have significant involvement in the 
modification of the hippocampus due to stress-causing stimuli (Nestler et al., 2002), and its 
overexpression elicits cellular and behavioral effects of antidepressant treatments (Shirayama et al., 
2002). It has also been known that cAMP response element-binding protein (CREB) is a 
transcription factor that mediates gene expressions activated by cAMP cascade, CREB mediates 
neurogenesis, survival of neurons, and response to antidepressant-like effects (Duman et al., 2000). 
Antidepressant drugs counteract the cascade of cAMP–CREB in the pathophysiology of 
depression (Gass and Riva, 2007), and CREB has been suggested to be a potential molecular 
mechanism of antidepressants that maintains a balance to stressful disturbance by phosphorylation 
of CREB (pCREB) (Kwon et al., 2008). In addition, it has been demonstrated that CREB acts as 
an upstream transcription factor of BDNF and permits a transcriptional alternation in BDNF 
expression following antidepressant treatment (Conti et al., 2002). ERK (extracellular 
signal-regulated kinase) is one of the most-researched member of the MAPK (mitogen-activated 
protein kinase) family, and in previous studies it has been suggested that the ERK may take part in 
the molecular mechanism of depression (Qi et al., 2006). Moreover, ERK pathway is a down 
stream signal transduction protein activated by BDNF (Mebratu and Tesfaigzi, 2009) and the 
antidepressant treatment can induce the phosphorylation of ERK (phospho-ERK1/2, p-ERK1/2) 
(Mattson et al., 2004). Taken together, these results indicate that BDNF, CREB and ERK could be 
potential molecular targets in the treatment of depression. 
In this study, we explored the antidepressant-like effect of PS, and its behavioral effects in 
mice were evaluated in the open field test (OFT), forced swim test (FST) and tail suspension test 
(TST).This was followed by a CUMS (chronic unpredictable mild stress) model to establish a 
depression situation followed by sucrose preference test. Furthermore, serum corticosterone, 
BDNF protein levels, and the phosphorylated levels of CREB and ERK were also assessed in the 
hippocampus of rats to investigate the potential mechanisms of action. 
2. Method 
2.1 Animals and Overall experimental plan 
Male ICR (Institute of Cancer Research) mice weighing between18–22 g and male SD 
(Sprague Dawley) rats weighing between 230–260 g were obtained from Second Military Medical 
University (SMMU) Animal Center. The animals were housed under standard conditions (12 h 
light/dark cycle; 24–26℃ ambient temperature; 55 ± 10% relative humidity) for one week with 
free access to food and water. All experimental procedures were approved by the Animal Care and 
Use Committee at SMMU and complied with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (Publication No. 85–23, revised 1985). The overall 
experimental plan is shown in Figure 1A. 
2.2 Drug administration and experimental groups 
The aerial parts of PS (15 kg) were collected from Xishuangbanna of Yunnan Province, PR 
China, and identified by one of the authors (Lu-Ping Qin). A voucher specimen 
(No.SYX20131217) was deposited at the Department of Pharmacognosy, School of Pharmacy, 
SMMU. The air–dried powder of the plant material (15 kg) was exhaustively extracted with 
ethanol. The resulting ethanol extract of PS (1.5 kg) was suspended in H2O and further partitioned 
into four fractions: petroleum ether (375 g, PSS), dichloromethane (150 g, PSR), ethyl acetate 
(150 g, PSY), butyl alcohol (225 g, PSZ). Fluoxetine hydrochloride was purchased from Lilly 
Suzhou Pharmaceutical Co., LTD. HP extract was purchased from Zhejiang HUISONG 
Pharmaceutical Co., LTD. All drugs were dissolved in H2O and diluted to the desired 
concentration on the day of experiment, and all of the drugs were administered by intragastric 
administration. Drugs and H2O as a vehicle were administered between 8:30 a.m. and 9:30 a.m. 
once a day for 7 consecutive days. The observers of behavior test were unaware of the treatment 
of the animals. 
2.2.1 Experiment groups of the PS extracts in mice 
After one-week of adaptation, the mice were randomly assigned to the following 5 groups 
(n=10 each): control group (received H2O as a vehicle), fluoxetine (FLX) group (20 mg/kg 
fluoxetine), PSL (50 mg/kg PS extracts), PSM (100 mg/kg PS extracts), PSH (200 mg/kg PS 
extracts) groups . 
2.2.2 Experiment groups of the different fractions of PS extracts in mice 
After the one–week adaptation period, the mice were randomized into 15 groups (n=10 each), 
including: control group (received H2O as a vehicle); fluoxetine group (20 mg/kg fluoxetine); HP 
group (250 mg/kg extracts of HP); 3 PSS treatment groups (30, 60,120 mg/kg PSS); 3 PSR 
treatment groups (12.5, 25,50 mg/kg PSR); 3 PSY treatment groups (12.5, 25,50 mg/kg PSY); 3 
PSZ treatment groups (20, 40,80 mg/kg PSZ). 
2.2.3 Experiment groups of the PSY in rats 
At the end of the one week adaption period, the rats were randomly assigned into 6 groups 
(n=10 each), including an unhandled control group (received H2O as a vehicle); a CUMS group 
(received H2O as a vehicle, CUMS); a fluoxetine (FLX) treatment group (12 mg/kg fluoxetine + 
CUMS); and 3 PSY treatment groups (7.5, 15, 30mg/kg PSY + CUMS). 
2.3 Open field test (OFT) 
Spontaneous activity was measured by an OFT performed as described previously (Liu et al., 
2013) with slight modification. For OFT, 1 h after the last treatment, mice were individually 
placed in a wooden box (50×50×30 cm) with the floor divided into 49 equal squares marked with 
black lines. The mice were placed in the central square and observed for 5 min. The following 
behaviors were recorded: the number of crossing (the number of squares crossed); rearing (the 
frequency of standing on hind limbs); and grooming (number of times the animal made like 
grooming of the face, licking/cleaning and scratching the various parts of the body). The OFT 
arena was thoroughly cleaned between each test. 
2.4 Forced swimming test (FST) 
FST was carried out according to a previously described method (Porsolt et al., 1978) with 
minor modifications. In briefly,1 h after the last drug administration, mice were individually 
placed into a glass cylinder (30 cm in height, 15 cm in diameter) filled with 12 cm high water 
(24–26℃), which ensured that the mice could not support themselves by touching the bottom. All 
mice were forced to swim for 6 min, and the immobility time during the final 4 min interval of the 
test was recorded. Immobility time was defined as the time spent by the mouse floating in the 
water without struggling (climbing walls or diving), and making only those small movements 
necessary to keep its head above the water. 
2.5 Tail suspension test (TST) 
The TST is an another well-known animal model for assessing antidepressant activity. The 
total duration of immobility induced by tail suspension was measured according to the method 
described previously (Steru et al., 1985). Briefly, 1 h after the last drug administration, mice were 
suspended 50 cm above the floor for 6 min by adhesive tape placed approximately 1 cm from the 
tip of the tail. Immobility time during the final 4 min of the testing period was recorded. Mice 
were considered immobile only when they hung passively and completely motionless. 
2.6 Chronic unpredictable mild stress (CUMS) procedure 
The CUMS procedures were performed as described previously (Willner et al., 1992) with 
minor modifications. Briefly, rats in stressed groups were exposed to the two of the stressors daily 
for 4 consecutive weeks (Figure 1B). These stressors were randomly scheduled over a one-week 
period and repeated with unpredictable sequence during the following 3 weeks. Non-stressed 
animals were left undisturbed in their home cages except during housekeeping procedures such as 
cage cleaning. Rats in the treatment group received treatment daily at 30 min before the stress 
exposure on days 21–28; the control and CUMS group rats were given water as a vehicle-only 
equivalent to the drug treatment. 
  
Figure 1: The overall experimental plan of our research about the antidepressant-like effect of PS (Piper sarmentosum Roxb.) and 
PSY (ethyl acetate fraction of PS) (A). Schedule of CUMS procedure (B). The CUMS protocol consisted of the sequential application of a 
variety of mild stressors. These stressors were randomly scheduled over a one-week period from Day 1 to 7 and repeated for 3 weeks. 
2.7 Sucrose preference test 
The sucrose preference test was performed as described previously (Luo et al., 2008) with 
minor modifications. Test was carried out at the end of 4–week CUMS exposure. Briefly, 72 h 
before the test, rats were trained to drink 1% sucrose solution (w/v): two bottles of 1% sucrose 
solution were placed in each cage, and 24 h later 1% sucrose in one bottle was replaced with tap 
water for 24 hours. At the end of adaptation, rats were deprived of water and food for 24 hours. 
Sucrose preference test was conducted at 9:00 a.m., in which rats were housed in individual cages 
and were permitted to access to two bottles containing 100 mL of sucrose solution (1%, w/v) and 
100 mL of water, respectively. After 1 h, the volumes of consumed sucrose solution and water 
were measured, and sucrose preference was calculated by the following formula:  
Sucrose preference = 
Sucrose consumption 
× 100%. 
Water consumption + sucrose consumption 
 
2.8 Measurement of serum corticosterone (CORT) concentration 
24 h after the sucrose preference test, rats were deeply anesthetized with chloral hydrate, and 
blood was collected from the abdominal aorta and placed on ice. Serum was separated by 
centrifugation at 3500 × g for 10 min at 4℃ and stored at –80℃ until assay. The concentration of 
serum CORT was measured using a commercially available ELISA (enzyme-linked 
immunosorbent assay) kit (WUHAN BEINGLAY BIOTECH Co., LTD., Wuhan, Hubei, China). 
The ELISA was performed according to the manufacturer’s instruction. 
2.9 Quantitative real-time PCR 
After the blood samples had been collected, the rats were sacrificed by decapitation. The 
brains were rapidly removed and the hippocampus was carefully dissected on ice and quickly 
frozen at –80℃. Five hippocampi in each group were selected randomly to homogenize, and total 
RNA was extracted from the hippocampus with TRIzol reagent (Invitrogen, USA). The cDNA was 
synthesized using a commercial RT-PCR (reverse transcription-polymerase chain reaction) kit 
(Fermentas, Vilnius, Lithuania) according to the manufacturer's instructions. Real-time PCR was 
performed on an ABI Prism 7300 Sequence Detector system using a SYBR Green PCR kit 
(Thermo, USA) and normalized to GAPDH under the following conditions: initial denaturation at 
95℃ for 10 min, followed by 40 cycles at 95℃ for 15 s, 60℃ for 45 s. At the end of the PCR 
reaction, a melting curve was obtained by holding at 95℃ for 15 s, cooling to 60℃ for 1 min, 
and then 95℃ for 15 s, 60℃ for 15 s. The primers used were as follows: BDNF: forward, 
5'-TAGGCAGAATGAGCAATGTC-3'; reverse, 5'-CCCAAGAGGTAAAGTGTAGAAG-3'; 
GAPDH: forward, 5'-GTCGGTGTGAACGGATTTG-3'; reverse, 
5'-TCCCATTCTCAGCCTTGAC-3'. The relative quantity was calculated according to 2−
ΔΔCt 
method (Livak and Schmittgen, 2001).  
2.10 Western blot analysis 
Rats were decapitated after blood collection, and the brain of each animal was quickly 
removed and the hippocampus was carefully dissected on ice and rapidly frozen at −80℃. Frozen 
hippocampus tissues (n=5/group) were homogenized in RIPA buffer containing protein inhibitors 
and phosphatase inhibitors with an ice bath. The homogenate was centrifuged at 12,000 × g (4℃) 
for 10 min and supernatants were collected. Protein concentration in the supernatants of 
hippocampus tissue extracts was estimated by a BCA protein assay kit (Thermo, USA). A same 
quantity (35μg) of protein from each hippocampus was loaded and separated by 10% SDS/PAGE 
gel electrophoresis and then transferred onto a polyvinylidene difluoride membrane (Millipore, 
USA). Transferred membranes were blocked with 5% skim milk (or with BSA for phosphorylated 
protein) for 1 h, incubated overnight at 4℃ with primary antibodies: BDNF (1:500,Santa Cruz 
Biotechnology, USA), ERK1/2 (1:1000, Santa Cruz Biotechnology, USA), phospho-ERK1/2 
(1:1000, Santa Cruz Biotechnology, USA), CREB (1:500, Santa Cruz Biotechnology, USA), 
phosphor-CREB (1:500, Santa Cruz Biotechnology, USA), GAPDH (1:1000, Santa Cruz 
Biotechnology, USA), and then incubated with a horseradish peroxidase-conjugated secondary 
antibody (1:1000, Santa Cruz Biotechnology, USA) for 1h at 37℃. The blots were developed 
using enhanced chemiluminescence (ECL) (Pierce, USA). The optical density of the protein bands 
was scanned and analyzed using ImageJ2x software (National Institutes of Health, USA). 
2.11 Statistical analysis 
All statistical analyses were performed using SPSS (Statistical Package for the Social 
Sciences) software version 19.0. The results were expressed as mean ± SEM. All data were 
statistically analyzed by one-way analysis of variance (ANOVA), followed by a post hoc LSD 
(least-significant difference) test. The differences were considered statistically significant when 
P＜0.05. 
3. Results 
3.1 Antidepressant-like effects of PS extracts in the FST and TST in mice 
In the FST, the results showed that PS extracts produced a strong antidepressant-like effect as 
well as fluoxetine (Figure 2A).The data were analyzed by a one-way ANOVA with drug treatment 
as the factor and revealed a significant effect of drug treatment (F[4,45]=26.325, P＜0.001). 
Subsequent LSD as post hoc analysis indicated that doses of PS extracts from 50 to 200 mg/kg 
decreased the immobility time in the FST in a dose-dependent manner, as immobility time was 
significantly reduced at the dose of 50, 100, 200 mg/kg of PS extracts (P<0.05; P<0.01; P<0.001, 
vs. control), fluoxetine also produced a significant reduction in immobility time (P<0.001, vs. 
control). Data from TST (Figure 2B) also revealed a significant effect of drug treatment 
(F[4,45]=3.006, P＜0.05). The LSD showed that a significant reduction in immobility time has 
been found in the PS treatment groups (100, 200 mg/kg; P＜0.01, P＜0.01) and fluoxetine group 
(P＜0.01) compared with controls. A dose-dependent effect in PS treatment groups has also been 
showed.
 
Figure 2 Antidepressant-like effect of PS (Piper sarmentosum Roxb.) in mice in the FST (forced swimming test) and TST (tail 
suspension test). The mice were treated with water (control), fluoxetine and PS. PS decreased the immobility time in the FST in a 
dose-dependent manner (A). PS decreased the immobility time in the TST in a dose-dependent manner (B). PS had no effect on the 
spontaneous activity in the OFT (open field test) (C). The data are presented as the mean ± SEM (n=10). *P < 0.05, **P < 0.01 and ***P 
< 0.001 compared with the control group. 
 
3.2 Effects of PS extracts on the spontaneous activity in the OFT 
To exclude the possibility that the antidepressant-like effects in these two tests might be due 
to differences in locomotor activity (e.g. increases in locomotor activity causing a reduction in 
immobility), mice were subjected to OFT. The results (Figure 2C) showed that there was no 
significant difference in the number of crossing (F[4,45]=0.426, P=0.789), rearing (F[4,45]=0.008, 
P=1.000), grooming (F[4,45]=0.306, P=0.873) and total movement (F[4,45]=0.305, P=0.873) in 
all groups. Furthermore, it was demonstrated that PS extracts had no effect on locomotor activity, 
indicating that the reduction of immobility time observed in the FST and TST after PS treatment 
was not due to spontaneous locomotor hyperactivity. 
3.3 Antidepressant-like effects of different fractions of PS extracts in the FST and TST in mice 
To further explore the antidepressant-like effects of PS, the extracts were partitioned into four 
fractions (PSS, PSR, PSY and PSZ) according to the polarity of constituents. The data in FST 
(Figure 3A) showed a significant difference in immobility time reduction of different drug 
treatments (F[14,135]=8.022, P＜0.001). The further LSD test indicated that, compared with 
controls, FLX group (P <0.001), HP group (P <0.001), PSS groups (30, 60, 120 mg/kg; P＜0.05, 
P＜0.05, P＜0.01), PSR group (50 mg/kg; P＜0.01) and PSY groups (12.5, 25, 50 mg/kg; P＜
0.01, P＜0.001, P＜0.001) significantly reduced the immobility time. In TST (Figure 3B), a 
significant reduction of immobility time (F[14,135]=7.711, P＜0.001) has also been discovered 
among treatment groups. The result of LSD showed that PSY (12.5, 25, 50 mg/kg; P＜0.05, P＜
0.001, P＜0.001) made a significant reduction in immobility time as well as FLX (P＜0.001) and 
HP (P＜0.001) compared to the control group. 
 
Figure 3 Different fractions of PS extracts produced antidepressant-like effect in mice in the FST and TST. The mice were treated 
with water (control), FLX, HP extracts, PSS, PSR, PSY and PSZ. PSS (30, 60, 120 mg/kg), PSR (50 mg/kg) and PSY (12.5, 25, 50 mg/kg) 
decreased the immobility time in the FST (A). PSY (12.5, 25, 50 mg/kg) decreased the immobility time in the TST in a dose-dependent 
manner (B). Different fractions of PS extracts had no effect on the spontaneous activity in the OFT (C). The data are presented as the 
mean ± SEM (n=10). *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the control group. 
 
3.4 Effects of different fractions of PS extracts on the spontaneous activity in the OFT 
In the OFT, the results (Figure 3C) showed that there was no difference in the number of 
crossing (F[14,135]=0.423, P=0.965), rearing (F[14,135]=0.129, P=1.000), grooming 
(F[14,135]=0.273, P=0.996) and total movement (F[14,135]=0.341, P=0.987) in all groups, 
proving that the drug treatments had no effect on spontaneous activity. This indicates that the 
reduction in immobility time observed both in FST and TST after PS administration was not 
related to locomotor hyperactivity. 
3.5 PSY treatment reverses the CUMS-induced depressive behavior in rats 
The work with mice has indicated that PS extracts may have antidepressant-like effects, and 
constituents of the PSY may also display similar properties. Therefore, we decided to focus on 
PSY in the following studies. To make further efforts on characterizing the antidepressant-like 
effects of PSY, we applied CUMS, which is currently considered as one of the most predictive 
animal models of depression (Forbes et al., 1996). In present study, we examined the effects of 
PSY on the sucrose preference and bodyweight as indexes of stress-induced responses. In sucrose 
preference test, the data (Figure 4A) showed that CUMS procedure resulted in a significant 
decrease in the sucrose consumption compared with controls, while treatment groups dramatically 
reversed the CUMS-induced reduction (F[5,54]=2.759, P＜0.05). Post hoc analysis indicated that 
CUMS performed a significant reduction of sucrose consumption than control group (P＜0.01), 
and compared with CUMS group, FLX (P＜0.01) and PSY treatment groups (7.5, 15, 30 mg/kg; P
＜0.05, P＜0.05, P＜0.01) showed an increase in sucrose preference. The results not only 
demonstrated that CUMS model progressed successfully, but also indicated that PSY 
administration could reversed the CUMS-induced depressive behavior. The data of body weight 
gain was analyzed by ANOVA, and the results showed (Figure 4B) that the CUMS treatment 
significantly influenced body weight gain compared with controls (F[1,58]=105.818, P＜0.001), 
demonstrating that CUMS reduces the growth in body weight seen in controls. Then we analyzed 
the body weight gain of all groups except controls by ANOVA, the results showed that there was 
no significant difference (F[4,45]=0.686, P=0.606) in any of the CUMS treatment groups (with or 
without drug administration). 
3.6 PSY administration decreased the hyperactivity of the HPA axis induced by CUMS 
Secretion of corticosterone by the hyperactivity of HPA axis is one of the most important 
neuroendocrine response to stress-caused stimuli (Stokes, 1995). Accordingly, we assessed the 
effects of PSY on serum corticosterone levels. In our studies, the results revealed (Figure 4C) that 
there was a significant effect of drug treatment on serum corticosterone levels (F[5,54]=47.845, P
＜0.001) by one-way ANOVA. Post hoc LSD analysis revealed that CUMS significantly increased 
the concentration of corticosterone in serum compared to control group (P＜0.001). PSY (7.5, 15, 
30 mg/kg; P＜0.01, P＜0.001, P＜0.001) and FLX (P＜0.001) treatment groups had a significant 
reduction in serum corticosterone levels compared with CUMS group. The results indicated that 
PSY reduced the CUMS-induced increase of serum corticosterone as fluoxetine did. 
 Figure 4 PSY reverses depressive-like behaviour in the CUMS rats. Rats were exposed to CUMS for 4 weeks and received a daily 
treatment during the last week. PSY treatment increased the sucrose preference index compared to CUMS rats (A). The body weights of 
control rats were significantly higher than those of CUMS-exposed rats during the 4 consecutive weeks of CUMS; there was no 
significant difference between CUMS group and drug treatment groups (B). PSY treatment significantly reversed the CUMS-induced 
elevation of serum CORT levels (C). The data are presented as the mean ± SEM (n=10). ##P< 0.01 and ###P < 0.001 compared with the 
control group; *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the CUMS group. 
 
3.7 PSY restored the CUMS-induced decrease in the mRNA expression and protein levels of 
BDNF in the hippocampus of rats 
The mRNA expression and protein levels of BDNF in the hippocampus is important for 
neurogenesis in the brain and plays a critical role in current hypothesis of depression (Dranovsky 
and Hen, 2006). Accordingly, we measured the mRNA expression of BDNF in the hippocampus 
following CUMS. In our studies, the BDNF mRNA expression was expressed as a ratio of 
GAPDH mRNA expression. The results (Figure 5A) were analyzed with one-way ANOVA and 
demonstrated that there was a significant difference in the expression of BDNF mRNA 
(F[5,54]=70.006,P＜0.001). The following LSD test showed that the BDNF mRNA expression in 
hippocampus of CUMS significantly decreased than controls (P＜0.001), and compared with 
CUMS group, PSY(7.5, 15, 30 mg/kg; P＜0.05, P＜0.001, P＜0.001) and FLX (P＜0.001) 
treatment groups had a significant increase in BDNF mRNA levels. Moreover, we also measured 
the BDNF protein levels with Western blot method, and the data were expressed as a ratio to 
GAPDH protein levels. The results (Figure 5B) showed that there was a significant difference in 
BDNF protein levels among the different treatment groups(F[5,24]=5.400, P＜0. 01). LSD test 
demonstrated that there was an obvious decrease of BDNF protein levels in CUMS group (P＜
0.001) compared with control group. While the BDNF protein levels of PSY (15, 30 mg/kg; P＜
0.05, P＜0.01) and FLX (P＜0.05) treatment groups were significantly increased than CUMS 
group. These results indicated that PSY treatment reversed the ability of stress effect to decrease 
BDNF in the hippocampus. 
 
Figure 5 PSY treatment increases BDNF in the hippocampus of stressed rats. RT-PCR results showed that treatment with PSY 
reversed the decrease of BDNF mRNA expression in the hippocampus induced by CUMS (A). Western blotting results showed that PSY 
treatment increased the CUMS-induced reduction of BDNF protein in hippocampus (B). The data are presented as the mean ± SEM 
(n=10). ###P < 0.001 compared with the control group; *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the CUMS group. 
 
3.8 PSY increased the phosphorylation of CREB and ERK in the hippocampus of rats 
CREB is an important transcription factor for BDNF in hippocampus, and it has also been 
involved in the actions of antidepressants (Lane-Ladd et al., 1997).The ERK is another key signal 
pathway of BDNF, and the phosphorylation of both CREB and ERK1/2 has been proposed as an 
intracellular common mechanism of antidepressant (Gourley et al., 2008). Therefore, we examined 
the phosphorylation of CREB and ERK among the treatment groups in the hippocampus, the 
phosphorylation of CREB and ERK being expressed as a ratio of the pCREB/CREB and 
pERK/ERK. The results of CREB phosphorylation ratio (Figure 6A) showed that there was a 
significant effect among the treatment groups (F[5,24]=9.287, P＜0. 001) by one-way ANOVA. 
The following LSD test indicated that the ratio of CREB phosphorylation in CUMS group was 
significant lower than control group (P＜0. 001),and an obvious effect of increasing CREB 
phosphorylation was found in PSY (7.5, 15, 30 mg/kg; P＜0.05, P＜0.05, P＜0.01) and FLX (P
＜ 0. 001) treatment groups compared to CUMS. The same situation appeared in ERK 
phosphorylation, as the results shown (Figure 6B), there was a significant difference of ERK 
phosphorylation in treatment groups (F[5,24]=6.587, P＜0. 01). The post hoc LSD test 
demonstrated that, compared to controls, CUMS group had a significant decrease of ERK 
phosphorylation in hippocampus (P＜0. 001), while in PSY (7.5, 15, 30 mg/kg; P＜0.05, P＜0.01, 
P＜0.001) and FLX (P＜0.01) groups, the reduction of ERK phosphorylation levels induced by 
CUMS was completely reversed. These results indicated that PSY increased the phosphorylation 
level of CREB and ERK, which was obviously decreased by this model of depression. 
 
Figure 6 Effect of PSY on the protein phosphorylation of CREB and ERK1/2 in the hippocampus of CUMS rats. PSY reversed the 
reduction of CREB phosphorylation caused by CUMS in hippocampus (A). PSY restored the CUMS-induced inhibition of ERK1/2 
phosphorylation in hippocampus (B). The data are presented as the mean ± SEM (n=10). ###P < 0.001 compared with the control group; 
*P < 0.05, **P < 0.01 and ***P < 0.001 compared with the CUMS group. 
 
4. Discussion 
In our present study, we have demonstrated that PS and PSY produced powerful 
antidepressant-like effects in animal depression models, with comparable profiles to that observed 
for the established antidepressants, fluoxetine and HP. The results showed that administration of 
PS and PSY reduced immobility time in FST and TST, without the effect on spontaneous 
locomotor which was proved in OFT. PSY administration alleviated the depression-like behavior 
caused by CUMS, as indicated by an increased sucrose preference in rats. In addition, PSY 
treatment significantly reduced the serum corticosterone levels in rats, which had been elevated by 
CUMS. Moreover, PSY induced an increase of BDNF and up-regulated phosphorylated CREB 
and ERK protein levels in the hippocampus of rats similar to that obtained with fluoxetine. 
Immobility time is the characteristic behavior index in FST and TST, which reflects 
behavioral despair as seen in human depression (Steru et al., 1985). OFT is usually used to make 
sure that antidepressant-like effect is independent of spontaneous activity. Our result indicated that 
treatment with PS or PSY produced significant antidepressant-like effects, when assessed in FST 
and TST, and the date of OFT demonstrated that PS and PSY had no effect on locomotor activity, 
indicating that the antidepressant-like activity of PS and PSY is specific. What is noteworthy is 
that, a dose-dependent effect of both PS (dose from 50 mg/kg to 200 mg/kg) and PSY (dose from 
12.5 mg/kg to 50 mg/kg) has been found in FST and TST. More importantly, the 
antidepressant-like effects of PS and PSY at high dose (PS: 200 mg/kg, PSY: 50 mg/kg) were 
similar to that of fluoxetine or HP, suggesting that PS may have the potential of being developed 
as a novel antidepressant. 
CUMS is a well-known effective model to imitate the pathogenesis of depression (Bhutani et 
al., 2009). In this study, rats in CUMS displayed representative anhedonia behavior, as indicated 
by their decreased sucrose preference. Anhedonia is a prominent symptom of depression. The  
preclinical analogues of the anhedonia scales and the procedures most commonly used to assess 
depression-like behaviour in rodents are the sucrose intake and preference tests (Der-Avakian and 
Markou, 2012). In the present study, our results confirmed that similar to fluoxetine, PSY 
treatment could reverse the decreased sucrose preference index, indicating a positive 
antidepressant-like effect of PSY. 
It is reported that the response to stress is mediated by the HPA axis, which is considered an 
important pathway in the pathogenesis of depression (Swaab et al., 2005). A potent stressor can 
activate the HPA axis hyperactivity, leading to the release of CORT into the blood. Treatment with 
some antidepressant drugs, such as fluoxetine attenuated the stress-induced elevation in serum 
CORT levels. Consistent with this hypothesis, in our present study, the CUMS caused 
hyperactivity of the HPA axis in rats, as indicated by the elevation of serum CORT, and 
administration of PSY and fluoxetine significantly reversed the CMUS-induced increase of serum 
CORT levels. Moreover, there is also a dose-dependent effect of PSY (from 12.5 mg/kg to 50 
mg/kg) to reduce serum CORT. It is indicated that the antidepressant-like effects of PSY were 
accompanied by alterations in the HPA axis. 
There is increasing evidence which suggests that high corticosterone concentration and 
chronic stress can result in the down-regulation of BDNF (Kunugi et al., 2010). Infusion of BDNF 
into the hippocampus area produced antidepressant-like behavioral effects in rats (Shirayama et al., 
2002). Therefore, it is indicated that BDNF is an important factor in the pathogenesis of 
depression, and increasing BDNF levels might be a common pathway for antidepressants to exert 
therapeutic functions (Swaab et al., 2005). In the present study, the results demonstrated that 
treatment with PSY reversed the CUMS-induced reduction of BDNF mRNA expression and 
protein levels in the hippocampus of rats. This effect of PSY was similar to the established 
antidepressant drug fluoxetine, which has been reported previously with effect of increasing 
BDNF (Ubhi et al., 2012). Our results indicated that antidepressant-like effects of PSY were 
related to the alteration of BNDF levels. 
We also examined the changes in CREB and ERK activities. The cAMP signaling pathway 
has been implicated in antidepressant-like effect after chronic treatment and there is an obvious 
connection to BDNF. As a transcription factor, CREB plays a critical role in neuronal plasticity 
and neurogenesis which enhance stress response and etiology of depression, and it is activated 
through phosphorylation. Increasing evidence points to the fact that stress exposure is associated 
with the reduction of CREB expression in hippocampal (Alfonso et al., 2006). Previous studies 
suggest that decreasing CREB function may contribute to clinical depression pathophysiology, and 
the increasing of it may also be an important part of the antidepressant response in humans 
(Pittenger and Duman, 2008). Additionally, it has been reported that CREB up-regulation may 
activate down stream targets, one of these targets being BDNF (Tao et al., 1998). The expression 
of BDNF is dependent on CREB activation and this procedure may be a key point of the 
therapeutic responses to antidepressants (Nair and Vaidya, 2006). MAPK is a major signal system 
that regulates cellular responses and activation of the MAPK cascade plays an important role in 
the pathophysiology of depression (Roux and Blenis, 2004). It has been indicated that inhibition of 
MAPK produces a depressive phenotype and blocks behavioral effects of antidepressants. ERK 
including ERK1 and ERK2 belongs to the MAPKs family, and accumulating evidences suggest 
that ERK signal path way may take part in pathogenesis of depression and the mechanism of 
antidepressant-like action (Gourley et al., 2008). ERK is one of the most-studied intracellular 
signaling pathways and it is highly sensitive to stress and closely associated with mood processing 
(Gerrits et al., 2006; Rubinfeld and Seger, 2005). Moreover, recent studies have demonstrated a 
positive modulation of ERK1/2 by antidepressant drugs such as fluoxetine (Kuo et al., 2013). 
Additionally, accumulating evidences suggest that activation of ERK might be attributable to 
BDNF-mediated neuronal function. ERK1/2 was persistently activated by a long-lasting induction 
of BDNF, in a social defeat stress model, suggesting a key role for ERK1/2 in BDNF expression 
(Berton and Nestler, 2006; Leem et al., 2014). In the present study, the results further confirm that 
exposure to CUMS was able to inactivate the CREB and ERK 1/2 as signaling and transcription 
factors in the hippocampus through phosphorylation, and it was also demonstrated that 
administration of PSY was able to reverse CUMS-induced decrease in phosphorylation of CREB 
and ERK 1/2, as well as classic antidepressant fluoxetine. These results suggest the involvement 
of CREB and ERK in the antidepressant-like effects of PSY. Furthermore, a growing number of 
studies suggests that CREB is a transcription factor and downstream target of ERK signal pathway 
(Xing et al., 1996). It is reported that the increasing of CREB phosphorylation by fluoxetine is 
accompanied by the up-regulation of ERK activation, suggesting an important role of the ERK 
signal pathway in the increase of CREB phosphorylation (Qi et al., 2008). ERK activity is able to 
induce phosphorylation of CREB at a specific serine residue, serine133, producing an active 
transcription complex enabling target gene activation (Conkright et al., 2003), and it is 
demonstrated that ERK-CREB signal system may play a critical role in the molecular mechanism 
of depression (Guan et al., 2013). In summary, ERK, CREB and BDNF-mediated signal pathways 
are indicated to be implicated in the neuroplasticity alterations induced by antidepressants 
(Covington et al., 2010; Vialou et al., 2013). These previous studies suggest that a 
CREB-BDNF-ERK circle signal pathway may be involved in the pathogenic mechanism of 
depression. So, combined with our results, we suggest that PSY induces antidepressant-like effect 
either on one or multi-target systems in CREB-BDNF-ERK circle signal pathway. 
Nowadays, it is well-known that many chronic and complex diseases have a complicated 
pathophysiology mechanism. These diseases are not regulated by a single molecular target but 
caused by multi-factorial, and there are often multiple ways or alternate processes that may be 
switched on in response to the inhibition of a specific target (Home et al., 2009; Rather et al., 
2013), for which a new technical term polypharmacology has been proposed (Efferth and Koch, 
2011; Xie et al., 2012). Depression is one of these multi-target diseases, and various hypothesis or 
protein factors participate in its pathogenesis, such as monoaminergic hypothesis, HPA axis 
hypothesis, BDNF, CREB and ERK signaling pathways. It is suggested that a balanced 
modulation of several targets can offer a better therapeutic effect with less side effects compared 
to a single selective ligand, significantly in the treatment of chronic and complex diseases 
(Morphy et al., 2004). In recent years, the development of new drugs aimed at a single molecular 
target has showed a down trend (Firman et al., 2012). At present, efforts are devoted to finding 
new therapeutics focus on multiple targets, which has become a novel direction in drug discovery 
(Zhang, 2005). There are two available strategies to meet the multiple targets implicated in 
complex diseases such as depression. The first one makes an attempt on utilizing a single 
compound to hit the multiple targets, another one is employing two or more active ingredients 
being constituted in one drug to hit the multiple targets. Therefore, it is worthy to pay attention to 
that some natural products can affect multiple targets to generate multiple pharmacological 
activities, producing significant physiological effects, and providing benefits due to the synergistic 
action that cannot be observed with a single compound (Chan and Loscalzo, 2012). These 
characteristics, along with their reliable clinical application, have thrust traditional Chinese herbal 
medicines into the limelight again, and scientists worldwide are becoming increasingly interested 
in the evaluation of herbal medicines products. PS is one of the Chinese herbal medicines, and in 
present studies, the antidepressant-like effect of PS extract and PSY may due to the action of their 
bioactive ingredients on multiple targets, such as HPA axis, BDNF, CREB and ERK.  
In conclusion, the present studies show that PS and PSY extracts exerted antidepressant-like 
effect in animal models of depression. Moreover, it is indicated that the increased expression of 
BDNF, phosphorylated CREB, phosphorylated ERK1/2 and the hyperactivity of HPA axis may be 
involved in the mechanism by which PS is effective as an antidepressant. However, further work 
is required to make PS into a novel antidepressant with higher efficacy and fewer side effects. 
 
Contributors 
Prof. Lu-Ping Qin and Prof. Ting Han designed the study, and wrote the protocol and the first 
draft of the manuscript. Yue Gao managed the literature searches. Qing Li performed animal 
model experiments and managed the statistical analyses. Fa-Lin Qu performed the gene 
expression experiments. Yi-Ping Jiang, Khalid Rahman and Kuo-Hsiung Lee wrote parts of the 
manuscript. All authors contributed to and have approved the final manuscript. 
 
Conflict of interest 
All authors declare that they have no conflicts of interest. 
 
Acknowledgements  
This work was supported by the Science & Technology Pillar Program in TCM (traditional 
Chinese medicine) of Science & Technology Commission of Shanghai (14401902900) and The 
Youth Breeding Project in Medical Science of the whole Army (13QNP098). These institutions 
had no role in the study design, the collection, analysis, or interpretation of the data, the writing of 
the report, or the decision to submit the paper for publication. The authors gratefully acknowledge 




Alfonso, J., Frick, L.R., Silberman, D.M., Palumbo, M.L., Genaro, A.M., Frasch, A.C., 2006. Regulation of 
hippocampal gene expression is conserved in two species subjected to different stressors and 
antidepressant treatments. Biological psychiatry 59, 244-251. 
Amran, A.A., Zakaria, Z., Othman, F., Das, S., Al-Mekhlafi, H.M., Nordin, N.-A.M., 2011. Changes in the 
vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and c-reactive protein following 
administration of aqueous extract of piper sarmentosum on experimental rabbits fed with cholesterol 
diet. Lipids in health and disease 10, 2. 
Berton, O., Nestler, E.J., 2006. New approaches to antidepressant drug discovery: beyond 
monoamines. Nature Reviews Neuroscience 7, 137-151. 
Bhutani, M.K., Bishnoi, M., Kulkarni, S.K., 2009. Anti-depressant like effect of curcumin and its 
combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and 
neurochemical changes. Pharmacology Biochemistry and Behavior 92, 39-43. 
Cassano, P., Fava, M., 2004. Tolerability issues during long-term treatment with antidepressants. 
Annals of Clinical Psychiatry 16, 15-25. 
Chan, S.Y., Loscalzo, J., 2012. The emerging paradigm of network medicine in the study of human 
disease. Circulation research 111, 359-374. 
Conkright, M.D., Canettieri, G., Screaton, R., Guzman, E., Miraglia, L., Hogenesch, J.B., Montminy, M., 
2003. TORCs: transducers of regulated CREB activity. Molecular cell 12, 413-423. 
Conti, A.C., Cryan, J.F., Dalvi, A., Lucki, I., Blendy, J.A., 2002. cAMP response element-binding protein is 
essential for the upregulation of brain-derived neurotrophic factor transcription, but not the 
behavioral or endocrine responses to antidepressant drugs. The Journal of neuroscience 22, 
3262-3268. 
Covington, H.E., Vialou, V., Nestler, E.J., 2010. From synapse to nucleus: novel targets for treating 
depression. Neuropharmacology 58, 683-693. 
Der-Avakian, A., Markou, A., 2012. The neurobiology of anhedonia and other reward-related deficits. 
Trends in Neurosciences 35, 68-77. 
Dranovsky, A., Hen, R., 2006. Hippocampal neurogenesis: regulation by stress and antidepressants. 
Biological psychiatry 59, 1136-1143. 
Duman, R.S., Malberg, J., Nakagawa, S., D’Sa, C., 2000. Neuronal plasticity and survival in mood 
disorders. Biological psychiatry 48, 732-739. 
Efferth, T., Koch, E., 2011. Complex interactions between phytochemicals. The multi-target therapeutic 
concept of phytotherapy. Current drug targets 12, 122-132. 
Estai, M.A., Soelaiman, I.N., Shuid, A.N., Das, S., Ali, A.M., Suhaimi, F.H., 2011. Histological changes in 
the fracture callus following the administration of water extract of Piper sarmentosum (Daun Kadok) in 
estrogen-deficient rats. Iranian journal of medical sciences 36, 281. 
Firman, K., Evans, L., Youell, J., 2012. A Synthetic Biology Project–Developing a single-molecule device 
for screening drug–target interactions. FEBS letters 586, 2157-2163. 
Forbes, N.F., Stewart, C.A., Matthews, K., Reid, I.C., 1996. Chronic mild stress and sucrose 
consumption: validity as a model of depression. Physiology & behavior 60, 1481-1484. 
 
Gass, P., Riva, M.A., 2007. CREB, neurogenesis and depression. Bioessays 29, 957-961. 
Gerrits, M., Westenbroek, C., Koch, T., Grootkarzijn, A., Ter Horst, G., 2006. Increased limbic 
phosphorylated extracellular-regulated kinase 1 and 2 expression after chronic stress is reduced by 
cyclic 17β-estradiol administration. Neuroscience 142, 1293-1302. 
Gourley, S.L., Wu, F.J., Kiraly, D.D., Ploski, J.E., Kedves, A.T., Duman, R.S., Taylor, J.R., 2008. Regionally 
specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. 
Biological psychiatry 63, 353-359. 
Guan, L., Jia, N., Zhao, X., Zhang, X., Tang, G., Yang, L., Sun, H., Wang, D., Su, Q., Song, Q., 2013. The 
involvement of ERK/CREB/Bcl-2 in depression-like behavior in prenatally stressed offspring rats. Brain 
research bulletin 99, 1-8. 
Hofman, M.A., Swaab, D.F., 2010. Increased expression level of corticotropin-releasing hormone in the 
amygdala and in the hypothalamus in rats exposed to chronic unpredictable mild stress. Neuroscience 
bulletin 26, 297-303. 
Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Komajda, 
M., McMurray, J.J., Team, R.S., 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral agent 
combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The 
Lancet 373, 2125-2135. 
Hou, C., Jia, F., Liu, Y., Li, L., 2006. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels 
in severe major depressive disorder. Brain research 1095, 154-158. 
Huang, Q., LI, Y., Liu, Y., 2005. A review of traditional usage for Piper sarmentosum Roxb. in the Yi 
nationality. Yunnan ethnic therapy and medicine 25, 56-58. 
Hussain, K., Ismail, Z., Sadikun, A., Ibrahim, P., Malik, A., 2008. Analysis of proteins, polysaccharides, 
glycosaponins contents of Piper sarmentosum Roxb. and anti-TB evaluation for 
bioenhancing/interaction effects of leaf extracts with Isoniazid (INH). Natural Product Radiance 7, 
402-408. 
Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., 
Wang, P.S., 2003. The epidemiology of major depressive disorder: results from the National 
Comorbidity Survey Replication (NCS-R). Jama 289, 3095-3105. 
Krishnan, V., Nestler, E.J., 2008. The molecular neurobiology of depression. Nature 455, 894-902. 
Kunugi, H., Hori, H., Adachi, N., Numakawa, T., 2010. Interface between hypothalamic‐pituitary‐
adrenal axis and brain‐ derived neurotrophic factor in depression. Psychiatry and clinical 
neurosciences 64, 447-459. 
Kuo, J.-R., Cheng, Y.-H., Chen, Y.-S., Chio, C.-C., Gean, P.-W., 2013. Involvement of extracellular signal 
regulated kinases in traumatic brain injury-induced depression in rodents. Journal of neurotrauma 30, 
1223-1231. 
Kwon, M.-S., Seo, Y.-J., Shim, E.-J., Lee, J.-K., Jang, J.-E., Park, S.-H., Jung, J.-S., Suh, H.-W., 2008. The 
differential effects of emotional or physical stress on pain behaviors or on c-Fos immunoreactivity in 
paraventricular nucleus or arcuate nucleus. Brain research 1190, 122-131. 
Lane-Ladd, S.B., Pineda, J., Boundy, V.A., Pfeuffer, T., Krupinski, J., Aghajanian, G.K., Nestler, E.J., 1997. 
CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and 
behavioral evidence for a role in opiate dependence. The Journal of neuroscience 17, 7890-7901. 
Lecrubier, Y., Clerc, G., Didi, R., Kieser, M., 2002. Efficacy of St. John’s Wort Extract WS 5570 in Major 
Depression: A Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry 159, 1361-1366. 
Leem, Y.-H., Yoon, S.-S., Kim, Y.-H., Jo, S.A., 2014. Disrupted MEK/ERK signaling in the medial orbital 
cortex and dorsal endopiriform nuclei of the prefrontal cortex in a chronic restraint stress mouse 
model of depression. Neuroscience letters 580, 163-168. 
 
Liu, Y., Jia, G., Gou, L., Sun, L., Fu, X., Lan, N., Li, S., Yin, X., 2013. Antidepressant-like effects of tea 
polyphenols on mouse model of chronic unpredictable mild stress. Pharmacology Biochemistry and 
Behavior 104, 27-32. 
Livak, K.J., Schmittgen, T.D., 2001. Analysis of Relative Gene Expression Data Using Real-Time 
Quantitative PCR and the 2−ΔΔCT Method. Methods 25, 402-408. 
Luo, D., An, S., Zhang, X., 2008. Involvement of hippocampal serotonin and neuropeptide Y in 
depression induced by chronic unpredicted mild stress. Brain research bulletin 77, 8-12. 
Mattson, M.P., Maudsley, S., Martin, B., 2004. A neural signaling triumvirate that influences ageing and 
age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing research reviews 3, 445-464. 
Mebratu, Y., Tesfaigzi, Y., 2009. How ERK1/2 activation controls cell proliferation and cell death: Is 
subcellular localization the answer? Cell cycle 8, 1168-1175. 
Morphy, R., Kay, C., Rankovic, Z., 2004. From magic bullets to designed multiple ligands. Drug discovery 
today 9, 641-651. 
Nair, A., Vaidya, V., 2006. Cyclic AMP response element binding protein and brain-derived 
neurotrophic factor: molecules that modulate our mood? Journal of biosciences 31, 423-434. 
Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M., 2002. Neurobiology of 
depression. Neuron 34, 13-25. 
Pittenger, C., Duman, R.S., 2008. Stress, depression, and neuroplasticity: a convergence of 
mechanisms. Neuropsychopharmacology 33, 88-109. 
Porsolt, R.D., Anton, G., Blavet, N., Jalfre, M., 1978. Behavioural despair in rats: a new model sensitive 
to antidepressant treatments. European journal of pharmacology 47, 379-391. 
Qi, X., Lin, W., Li, J., Li, H., Wang, W., Wang, D., Sun, M., 2008. Fluoxetine increases the activity of the 
ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced 
swim stress. Neurobiology of disease 31, 278-285. 
Qi, X., Lin, W., Li, J., Pan, Y., Wang, W., 2006. The depressive-like behaviors are correlated with 
decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced 
swim stress. Behavioural brain research 175, 233-240. 
Rather, M.A., Bhat, B.A., Qurishi, M.A., 2013. Multicomponent phytotherapeutic approach gaining 
momentum: Is the “one drug to fit all” model breaking down? Phytomedicine 21, 1-14. 
Roux, P.P., Blenis, J., 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases 
with diverse biological functions. Microbiology and molecular biology reviews 68, 320-344. 
Rubinfeld, H., Seger, R., 2005. The ERK cascade: a prototype of MAPK signaling. Molecular 
biotechnology 31, 151-174. 
Sapolsky, R.M., 2000. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives 
of general psychiatry 57, 925-935. 
Sarko, J., 2000. Antidepressants, old and new: a review of their adverse effects and toxicity in 
overdose. Emergency medicine clinics of North America 18, 637-654. 
Sarris, J., Panossian, A., Schweitzer, I., Stough, C., Scholey, A., 2011. Herbal medicine for depression, 
anxiety and insomnia: a review of psychopharmacology and clinical evidence. European 
Neuropsychopharmacology 21, 841-860. 
SATCM, 1999. Chinese Materia Medica. Shanghai Scientific and Technical Publishers, Shanghai, pp. 
445-446. 
Shirayama, Y., Chen, A.C.-H., Nakagawa, S., Russell, D.S., Duman, R.S., 2002. Brain-derived 
neurotrophic factor produces antidepressant effects in behavioral models of depression. The Journal 
of Neuroscience 22, 3251-3261. 
Steru, L., Chermat, R., Thierry, B., Simon, P., 1985. The tail suspension test: a new method for 
screening antidepressants in mice. Psychopharmacology 85, 367-370. 
Stokes, P.E., 1995. The potential role of excessive cortisol induced by HPA hyperfunction in the 
pathogenesis of depression. European Neuropsychopharmacology 5, 77-82. 
Suhana Mohd Ramli, E., Suhaimi, F., Ahmad, F., Nazrun Shuid, A., Mohamad, N., Nirwana Soelaiman, I., 
2013. Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis. Current drug targets 14, 
1675-1682. 
Swaab, D.F., Bao, A.-M., Lucassen, P.J., 2005. The stress system in the human brain in depression and 
neurodegeneration. Ageing research reviews 4, 141-194. 
Szegedi, A., Kohnen, R., Dienel, A., Kieser, M., 2005. Acute treatment of moderate to severe 
depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind 
non-inferiority trial versus paroxetine. BMJ 330, 503. 
Tao, X., Finkbeiner, S., Arnold, D.B., Shaywitz, A.J., Greenberg, M.E., 1998. Ca 2+ influx regulates BDNF 
transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709-726. 
Teschke, R., Genthner, A., Wolff, A., 2009. Kava hepatotoxicity: Comparison of aqueous, ethanolic, 
acetonic kava extracts and kava–herbs mixtures. Journal of ethnopharmacology 123, 378-384. 
Thachil, A., Mohan, R., Bhugra, D., 2007. The evidence base of complementary and alternative 
therapies in depression. Journal of affective disorders 97, 23-35. 
Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A.A., 
Lebowitz, B.D., Biggs, M.M., 2006. Medication augmentation after the failure of SSRIs for depression. 
New England Journal of Medicine 354, 1243-1252. 
Ubhi, K., Inglis, C., Mante, M., Patrick, C., Adame, A., Spencer, B., Rockenstein, E., May, V., Winkler, J., 
Masliah, E., 2012. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic 
model mouse of α-synucleinopathy. Experimental neurology 234, 405-416. 
Ugusman, A., Zakaria, Z., Hui, C.K., Nordin, N.A.M.M., 2010. Piper sarmentosum increases nitric oxide 
production in oxidative stress: a study on human umbilical vein endothelial cells. Clinics 65, 709-714. 
Vialou, V., Feng, J., Robison, A.J., Nestler, E.J., 2013. Epigenetic Mechanisms of Depression and 
Antidepressants Action. Annual review of pharmacology and toxicology 53, 59. 
Willner, P., Muscat, R., Papp, M., 1992. Chronic mild stress-induced anhedonia: a realistic animal 
model of depression. Neuroscience & Biobehavioral Reviews 16, 525-534. 
Wu, Z., 2002. Flora of Xishuangbanna. Yunnan Science Press, Kunming, pp. 233-234. 
Xie, H., Yan, M.-c., Jin, D., Liu, J.-j., Yu, M., Dong, D., Cai, C.-c., Pan, S.-L., 2011. Studies on 
antidepressant and antinociceptive effects of ethyl acetate extract from Piper laetispicum and 
structure–activity relationship of its amide alkaloids. Fitoterapia 82, 1086-1092. 
Xie, L., Xie, L., Kinnings, S.L., Bourne, P.E., 2012. Novel computational approaches to 
polypharmacology as a means to define responses to individual drugs. Annual review of pharmacology 
and toxicology 52, 361-379. 
Xing, J., Ginty, D.D., Greenberg, M.E., 1996. Coupling of the RAS-MAPK pathway to gene activation by 
RSK2, a growth factor-regulated CREB kinase. Science 273, 959-963. 
Zhang, H.-Y., 2005. One-compound-multiple-targets strategy to combat Alzheimer’s disease. FEBS 
letters 579, 5260-5264. 
Zheng, X., Sun, W., Li, R., 2013. Ethnobotanical Study on Wild Vegetable Resources of Li Nationality. 
Hubei agricultural sciences 52, 3856-3860. 
 
